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Geniposide is a well-known iridoid glycoside compound and is an essential component of a wide variety of traditional
phytomedicines, for example, Gardenia jasminoides Elli (Zhizi in Chinese), Eucommia ulmoides Oliv. (Duzhong in Chinese),
Rehmannia glutinosa Libosch. (Dihuang in Chinese), and Achyranthes bidentata Bl. (Niuxi in Chinese). It is also the main
bioactive component of Gardeniae Fructus, the dried ripe fruit of Gardenia jasminoides Ellis. Increasing pharmacological evidence
supports multiple medicinal properties of geniposide including neuroprotective, antidiabetic, hepatoprotective, anti-inflammatory,
analgesic, antidepressant-like, cardioprotective, antioxidant, immune-regulatory, antithrombotic, and antitumoral effects. It has
been proposed that geniposide may be a drug or lead compound for the prophylaxis and treatment of several diseases, such
as Alzheimer’s disease, Parkinson’s disease, diabetes and diabetic complications, ischemia and reperfusion injury, and hepatic
disorders. The aim of the present review is to give a comprehensive summary and analysis of the pharmacological properties of
geniposide, supporting its use as a medicinal agent.
1. Introduction
Geniposide (C
17
H
24
O
10
; Figure 1), a well-known iridoid gly-
coside compound, is one of the main bioactive components
of traditional Chinese medicine Gardeniae Fructus, the dried
ripe fruit of Gardenia jasminoides Ellis (Zhizi in Chinese).
It has been isolated and identified in nearly 40 species of
plants and most of which are medicinal herbs [1]. Over
the past few decades, there has been a rapid growth in the
information available on the pharmacological activities of
geniposide. Studies have shown that geniposide displays a
wide spectrum of in vitro and in vivo pharmacological effects,
including neuroprotective, antidiabetic, hepatoprotective,
anti-inflammatory, analgesic, antidepressant-like, cardiopro-
tective, antioxidant, immune-regulatory, antithrombotic, and
antitumoral effects (summarized in Table 1), and these phar-
macological effects lay the foundation for geniposide of being
a potential therapeutic agent for the treatment of several
diseases, such as Alzheimer's disease (AD), Parkinson’s dis-
ease (PD), diabetes and diabetic complications, ischemia and
reperfusion injury, and hepatic disorders. The aim of the
present review is to give a comprehensive summary and
analysis of the pharmacological properties of geniposide,
supporting the potential uses of geniposide as a medicinal
agent.
2. Pharmacology Actions
2.1. Anti-Alzheimer’s Disease Activity. AD is the most com-
mon neurodegenerative disorder of progressive cognitive
decline in the aged population [2]. A number of stud-
ies have demonstrated the anti-AD activity of geniposide
both in vitro and in vivo. Formaldehyde is neurotoxic, and
long-term overdose increases the risk of AD. An increase
in the concentration of endogenous formaldehyde in the
brain has been found to correlate with dementia in aging
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Figure 1: Chemical structure of geniposide.
people. In human neuroblastoma SH-SY5Y cells, treatment
with geniposide at a concentration of 100 𝜇M ameliorated
the morphology of formaldehyde- (0.12 mM) injured cells.
Furthermore, geniposide increased the production of the
antiapoptotic gene Bcl-2 at both mRNA and protein levels,
while decreasing the expression of the proapoptotic gene P53,
apoptotic executer caspase-3, and apoptotic initiator caspase-
9. Moreover, geniposide elevated the activity of intracellular
antioxidants, including superoxide dismutase (SOD) and
glutathione peroxidase (GSH-Px) [3]. Incubation of murine
N2aneuroblastoma cellswith formaldehyde (0.09mM) for 24
h notably changed cell morphology, decreased cell viability,
and promoted apoptosis, and these effects were reversed by
supplementation with geniposide (200 𝜇M). In particular,
geniposide remarkably ameliorated morphology and cell
numbers, increased cell viability, upregulated the expression
of Akt and Bcl-2, and lowered the expression of FoxO3 and
p53 [4].
Amyloid plaques composed of insoluble amyloid-𝛽 (A𝛽)
deposits are a characteristic pathological feature of AD and
A𝛽 aggregated with oligomer is known to be able to induce
cellular toxicity as well as cognitive impairment. Incubation
with geniposide at 83.8 𝜇M reduced the cytotoxicity of
A𝛽 (10 𝜇M) in rat hippocampal neurons and promoted
the outgrowth of neurites both in their length and in the
dendrite number per neuron. Geniposide at 5, 100, and
200 𝜇M increased the cell viability of SY5Y-APP695sw cells
treated with A𝛽
42
aggregates. Furthermore, geniposide at 100
𝜇M promoted fibrillogenesis and increased the formation
of high molecular masses of A𝛽
42
polymers, resulting in a
decrease of the quantity and cytotoxicity of A𝛽
42
oligomers
[5]. Moreover, geniposide averted A𝛽
1−42
-induced cell injury
in primary cultured cortical neurons [6]. The receptor for
advanced glycation end products- (RAGE-) mediated signal-
ing pathway is related to A𝛽-induced pathogenic responses.
Geniposide at 50, 100, and 200 𝜇M suppressed RAGE-
mediated signaling (activation of extracellular regulated pro-
tein kinase (ERK) 1/2 and inhibited kappa B (I𝜅B)/nuclear
factor-𝜅B (NF-𝜅B)) and attenuated the production of tumor
necrosis factor-𝛼 (TNF-𝛼) and interleukin-1𝛽 (IL-1𝛽) in cul-
tured BV2 microglia cells treated with A𝛽
1-42 (5 𝜇M) [7]. In
primary hippocampal neurons, it increased synaptic plastic-
ity through alleviating the A𝛽-stimulated downregulation of
long-termpotentiation and elevating theminiature excitatory
postsynaptic current amplitude and frequency. In APP/PS1
transgenic mice, intragastric administration of geniposide
at 25 mg/kg for 3 months significantly inhibited RAGE-
mediated signaling, lowered the production of TNF-𝛼 and
IL-1𝛽, and suppressed cerebral A𝛽 accumulation. Moreover,
geniposide ameliorated learning and memory deficits [8].
A large body of evidence indicates that insulin-degrading
enzyme (IDE) plays an essential role in the degradation ofA𝛽.
Geniposide enhanced the expression of IDE in primary cor-
tical neurons, and this effect was reversed by LY294002 (an
inhibitor for phosphatidyl inositol 3-kinase, PI3K), GW9662
(an antagonist for peroxisome proliferator-activated receptor
𝛾, PPAR𝛾), AG1478 (an antagonist for epidermal growth
factor receptor), H89 (an inhibitor for protein kinase A,
PKA), and PP1 (an inhibitor for c-Src). Furthermore, it
upregulated the phosphorylation of PPAR𝛾 and promoted
the release of phosphorylated FoxO1 from nuclear fraction
to the cytosol. In addition, geniposide directly activated the
activity of IDE promoter in PC12 cells [9]. In neuroblastoma
SH-SY5Y cells, incubation with geniposide at 1 and 10 𝜇M
for 24 h notably augmented the level of IDE protein in a
concentration-dependent manner [10].
Furthermore, an increasing number of studies have
demonstrated that leptin has protective effect against AD.
Geniposide treatment inhibited the level of A𝛽
1-42 both in rat
primary cortical neurons (10 𝜇M) and in APP/PS1 transgenic
mice (10, 20, and 40 mg/kg, i.g.). Moreover, geniposide at
10 𝜇M induced the phosphorylation of Janus kinase 2 and
signal transducer and activator of transcription 3 (STAT3),
upregulated the protein level of ADAM10, and downregulated
the expression of BACE1 in rat primary cortical neurons,
and these effects were reversed by the preincubation with
leptin antagonist (50 ng/mL) [11]. Formation of intracellular
neurofibrillary tangle from hyperphosphorylated tau is one
of the typical hallmark lesions of AD as well. Administration
of geniposide enhanced the expression of leptin receptor and
diminished the phosphorylation of tau both in rat primary
cultured cortical neurons in vitro and in APP/PS1 transgenic
mice in vivo. Additionally, geniposide at 10 𝜇M induced the
phosphorylation of Akt at Ser-473 site and glycogen synthase
kinase-3𝛽 (GSK-3𝛽) at Ser-9 site in primary cultured cortical
neurons, and this effect of geniposide on Akt and GSK-3𝛽
as well as the effect of geniposide on tau phosphorylation
could be inhibited by leptin antagonist (50 nM) [12]. Treat-
ment with geniposide for 4 weeks also attenuated insulin
deficiency-induced phosphorylated level of tau and acceler-
ation of GSK-3𝛽 phosphorylation in the brain of APP/PS1
transgenic mice. It also augmented the effect of insulin on
the phosphorylation of tau, Akt, and GSK-3𝛽 in primary
cultured cortical neurons, and these effects were reversed by
LY294002 [13]. In streptozotocin- (STZ-) induced ADmodel
rats, injection of geniposide at 50 𝜇M to the lateral ventricle
reduced STZ-induced spatial learning deficit, tau phospho-
rylation, and GSK-3𝛽 hyperactivity. Additionally, it inhibited
STZ-stimulated neural pathology, including accumulation
of vesicles in synaptic terminal, paired helical filament-like
structures, abnormalities of endoplasmic reticulum (ER), and
early stage of apoptosis [14].
Moreover, oxidative stress and mitochondrial dysfunc-
tion appear early and contribute to the disease progression
in AD. Preincubation with geniposide at 2.5, 5, and 10 𝜇M
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exerted protective effects againstA𝛽-induced neuronal injury
by blocking mitochondrial dysfunction and oxidative stress.
In particular, geniposide ameliorated adenosine triphosphate
(ATP) generation, mitochondrial membrane potential levels,
cytochrome c oxidase and caspase-3/9 activity, attenuated
reactive oxygen species (ROS) production and cytochrome
c leakage and suppressed apoptosis in primary cultured
mouse cortical neurons incubation with oligomeric A𝛽
1-42 (5
𝜇M) [15]. Intragastric administration of geniposide notably
reduced mitochondrial dysfunction in APP/PS1 mice by
inhibiting the mitochondrial oxidative stress and elevat-
ing the mitochondrial membrane potential and activity of
cytochrome c oxidase [16]. Treatment with geniposide at 50
𝜇M for 2 h stimulated the expression of Bcl-2 in PC12 cells
induced by H
2
O
2
(100 𝜇M), and this effect was retarded
by preincubation with LY294002. Moreover, geniposide
increased the phosphorylation of Akt308, Akt473, GSK-3𝛽,
and phosphoinositide-dependent protein kinase 1, suggesting
that it protects against the oxidative damage induced byH
2
O
2
in PC12 cells via PI3K signaling pathway [17]. Collectively,
geniposide has the potential to be a drug or lead compound
for the treatment of AD.
2.2. Antidiabetic Activity and Inhibition of Diabetic Compli-
cations. Glucose-stimulated insulin secretion (GSIS) from
pancreatic 𝛽 cells is one of the key mechanisms in regulating
cellular adaptation demands to nutritional and metabolic
variations. In rat pancreatic INS-1 cells in vitro, geniposide
at 5 mM apparently enhanced GSIS, glucose uptake, and
ATP production, while at 25 mM it notably decreased
these three outcomes. Geniposide time-dependently induced
phosphorylation of acetyl-CoA carboxylase, a marker of
AMP-activated protein kinase (AMPK) activity, and this
effect was notably inhibited by compound C, a selective
AMPK inhibitor. Additionally, the knockdownofAMPKpro-
tein with AMPK small interfering RNA (siRNA) treatment
attenuated geniposide-regulated GSIS, glucose uptake, and
ATP production, suggesting that AMPK plays an essential
role in the regulatory effect of geniposide on GSIS [18].
In the presence of low (5.5 mM) or moderately high (11
mM) levels of glucose, geniposide at 10 𝜇M enhanced GSIS,
glucose uptake, and intracellular ATP level. However, it also
exerted a contrary role in the presence of a high (33 𝜇M)
level of glucose. Furthermore, geniposide ameliorated the
impairment of GSIS stimulated by glucose (33 𝜇M) [19].
Regulation of proteasome-dependent thioredoxin-
interacting protein degradation may be a novel strategy to
prevent the glucotoxicity in pancreatic 𝛽-cells. Geniposide
accelerated the degradation of thioredoxin-interacting
protein via proteasome pathway in high-glucose- (25 mM)
treated INS-1 cells. Moreover, geniposide obviously inhibited
MG132- (a proteasomal inhibitor) induced enhancement
of GSIS, glucose uptake, and metabolism [20]. In another
study, it induced insulin secretion, phosphorylation of
Akt473 and phosphoinositide-dependent protein kinase 1,
and the expression of glucose transporter 2. Furthermore,
it decreased the phosphorylation of downstream target
GSK-3𝛽, and this effect was reversed by LY294002 (10𝜇M)
[21]. The glucagon-like-1 receptor (GLP-1R) antagonist
exendin (9-39) (200 nM) or knockdown of GLP-1R gene
with short hairpin RNA interference offsets the effect of
geniposide on insulin secretion stimulated by glucose
(5.5 mM) [22]. Moreover, geniposide modulated pyruvate
carboxylase expression and the production of intermediates
of glucosemetabolism [19]. In rat pancreatic islets, geniposide
facilitated insulin secretion by activating GLP-1R and the
adenylyl cyclase/cAMP signaling pathway, and this effect
was blocked via inhibition of PKA. Moreover, geniposide
suppressed voltage-dependent potassium channels, and
this effect was alleviated via inhibition of GLP-1R or PKA.
Furthermore, it prolonged action potential duration and
activated Ca2+ channels [23].
𝛽-cell apoptosis is considered to be a major cause of
loss of 𝛽 cells in diabetes. Geniposide significantly inhib-
ited high-glucose- (25mM) induced cell damage in INS-
1 cell. Consistently, it upregulated the protein levels of cell
apoptosis-associated enzymes, including heme oxygenase-1
(HO-1) and Bcl-2, while decreasing the protein level of Bax,
and these effects were reversed by compound C, but were
potentiated by AICAR, an AMPK activator. Furthermore,
high glucose-induced cleavage of caspase-3 was prevented
by geniposide, and this effect was inhibited by compound
C. Additionally, the effects of geniposide on the apoptosis-
associated proteins and cell viability were attenuated by
AMPK siRNA [24]. Incubation with geniposide at 20 𝜇M
for 3 days promoted 𝛽-cell survival through accelerating 𝛽-
cell proliferation and inhibiting 𝛽-cell apoptosis in cultured
mouse islets after treatment with diabetic stimuli. Geniposide
protected𝛽-cell by activatingWnt signaling andAkt, promot-
ing expressions of T-cell factor 7-like 2 (TCF7L2) and GLP-
1R, suppressing GSK-3𝛽 activity, and increasing 𝛽-catenin
nuclear translocation, and this effect was obviously reversed
by siRNAs against 𝛽-catenin or by ICG001 (𝛽-catenin/TCF-
mediated transcription inhibitor). Intragastric administra-
tion of geniposide at 100mg/kg promoted 𝛽-cell regeneration
to normalize blood glucose in high-fat diet and db/db mice.
In exocrine cells isolated from mouse pancreas, it induced
duct cell differentiation by increasing TCF7L2 expression and
activating Janus kinase 2/STAT3 pathway [25]. In INS-1 cells,
pretreatment with geniposide for 7 h decreased palmitate-
induced 𝛽-cell apoptosis and active caspase-3 expression,
and this effect was reversed by exendin (9-39). Additionally,
geniposide ameliorated palmitate-stimulated impairment of
GLP-1R signaling by increasing the phosphorylation of Akt
and FoxO1 and elevating the expression of pancreatic and
duodenal homeobox 1 [26].
Islet amyloid deposition is increasingly seen as a patho-
genic feature of type 2 diabetes mellitus, with the deposits
containing the unique amyloidogenic peptide islet amyloid
polypeptide (IAPP, also known as amylin). Preincubation
with geniposide prevented human IAPP- (hIAPP-) induced
cell damage in INS-1E cells, and this effect was significantly
inhibited by bacitracin, an inhibitor of IDE activity. In addi-
tion, it induced the expression of IDE, a key degrading protein
of hIAPP, but had no obvious effect on the aggregation of
hIAPP, suggesting that geniposide prevents hIAPP-induced
cytotoxicity in INS-1E cells via upregulation of IDE expres-
sion [27]. In STZ-induced diabetic rats, geniposide at 12.5 and
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25mg/kg reduced the level of A𝛽
1-42 in the hippocampus and
at 12.5 mg/kg, it apparently inhibited STZ-induced reduction
of the expression of IDE in the hippocampus [10]. Intragastric
administration of geniposide at 5, 10, and 20 mg/kg for 4
weeks significantly reduced the levels of cerebral A𝛽 peptides
(A𝛽
1-40 and A𝛽1-42) in APP/PS1 transgenic mice treated with
STZ. Moreover, geniposide lowered the protein levels of
ADAM10 (associated with 𝛼-secretase) and increased the
expression of 𝛽-site APP-cleaving enzyme (BACE1, associ-
ated with 𝛽-secretase) and IDE both in STZ-treated ADmice
and in primary cultured cortical neurons. Geniposide at 10
𝜇Maugmented the effect of insulin via decreasingA𝛽
1-42 level
in primary cultured cortical neurons [28].
Furthermore, intragastric administration of geniposide
at 25 mg/kg for 46 days significantly lowered the level
of blood glucose, total cholesterol, and triglyceride, while
elevating blood insulin levels in STZ-induced diabetic rats
[10]. Treatment with geniposide at 200 and 400 mg/kg for
2 weeks reduced the blood glucose, insulin, and triglyceride
levels in type 2 diabetic mice induced by a high-fat diet and
STZ injection in a dose-dependent manner. Moreover, the
expression of hepatic glycogen phosphorylase and glucose-
6-phosphatase at mRNA and immunoreactive protein levels,
as well as enzyme activity, was decreased in these mice [29].
Geniposide dose-dependently suppressed hepatic glucose
production in HepG2 cells and different concentrations of
this bioactive compound stimulated AMPK, acetyl coenzyme
A synthetase and FoxO1 phosphorylation, and inhibited
the activities of phosphoenolpyruvate carboxykinase and
glucose-6-phosphatase. These effects were partially counter-
acted by suppression of AMPK activity via compound C
and by inhibition of AMPK𝛼 expression via siRNA, suggest-
ing that geniposide potentially ameliorates hyperglycemia
involving inhibition of hepatic gluconeogenesis via modula-
tion of the AMPK-FoxO1 signaling pathway [30].
In spontaneously obese type 2 diabetic mice, genipo-
side suppressed body weight and visceral fat accumulation,
alleviated abnormal lipid metabolism and intrahepatic lipid
accumulation, and ameliorated abnormal glucose tolerance
and hyperinsulinemia, suggesting that it has an insulin
resistance-alleviating effect [31]. Furthermore, it significantly
ameliorated renal function by decreasing levels of serum
creatinine, blood urea nitrogen, urinary albumin and elevator
renal index and attenuating glomerular basement membrane
in STZ-induced diabetic rats. Furthermore, geniposide inhib-
ited monocytes and T-cell infiltration and reduced produc-
tion of intercellular cell adhesion molecule-1, TNF-𝛼, IL-1,
and IL-6. Additionally, it suppressed the activation of NF-𝜅B
by decreasing expression ofNF-𝜅Bp65, IKK𝛼, and p-I𝜅B-𝛼 in
renal tissue, indicating that it is able to ameliorate structural
and functional abnormalities of kidney in diabetic rats [32].
Geniposide at 10-20𝜇Msuppressed adhesion ofmonocytes to
humanumbilical vein endothelial cells (HUVECs) stimulated
by high glucose (33 mM) in a concentration-dependent
manner. At a concentration of 5-40 𝜇M, it lowered high-
glucose-stimulated gene and protein expression of vascular
cell adhesion molecule 1 and E-selectin. At a concentration
of 5-20 𝜇M, it inhibited ROS production and blocked I𝜅B
degradation in the cytoplasm and NF-𝜅B translocation from
the cytoplasm to the nucleus in HUVECs, suggesting that
geniposide may have a role in the treatment for diabetic
vascular injury [33].
2.3. Anti-Parkinson’s Disease Activity. PD is a noncurable
chronic neurodegenerative disease at present and geniposide
has shown neuroprotective effects in PDmodels in several in
vivo and in vitro studies. In four 1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine- (MPTP-) (30 mg/kg, i.p.) induced acute
PDmodel mice, intraperitoneal injection of geniposide at 100
mg/kg for 8 days ameliorated bradykinesia and movement
balance and improved locomotor and exploratory activity.
In addition, MPTP treatment reduced tyrosine hydroxylase
positive neuron, lessened the level of Bcl-2, and increased
the level of Bax, the ratio of Bax/Bcl-2, and the activation
of caspase-3 in the substantia nigra. Nevertheless, these
alterations were reversed by geniposide, suggesting that the
neuroprotective activity of geniposide is associated with
upregulation of growth factor signaling and reduction of
apoptosis [34]. In human neuroblastoma SH-SY5Y cells
treated with N-methyl-4-phenylpyridinium iodide in vitro
and PD model mice induced by MPTP (20mg/kg) in vivo,
geniposide administration decreased microRNA-21 (miR-21)
level, increased lysosome-associated membrane protein 2A
(LAMP-2A) level, and lessened 𝛼-synuclein protein expres-
sion. LAMP-2A mediated the regulation of 𝛼-synuclein by
miR-21. The high expression of LAMP-2A retarded the
upregulation of 𝛼-synuclein induced by miR-21 mimic. The
downregulating effect of geniposide on 𝛼-synuclein was
reversed by miR-21 mimics/agomir, while it was augmented
bymiR-21 inhibitor, suggesting that geniposide exerts its neu-
roprotective effects through reducing 𝛼-synuclein expression
via the miR-21/LAMP-2A axis in PD models [35].
2.4. Inhibition of Ischemia and Reperfusion Injury. The pro-
tective effect of geniposide against ischemic brain injury has
been investigated in in vitro and in vivomodels and increasing
number of studies have focused on its therapeutic role in
ischemic cerebral disease. Oral administration of geniposide
at 50 mg/kg for 30 days exhibited an improved effect on
learning and memory ability and neural protective effects
in chronic cerebral ischemia model rats induced by perma-
nent occlusion of bilateral common carotid arteries [36].
Geniposide at 75 mg/kg regulated antiapoptotic functions
and suppressed blood-brain barrier leakage/haemorrhage by
increasing GluN2A-containing N-methyl-D-aspartate recep-
tor expression in transient middle cerebral artery occlusion
rats, and these effects could be counteracted by GluN2A
antagonist NVP-AAM077, but not the GluN2B inhibitor
ifenprodil. Furthermore, the protective effect of geniposide
was attributed to the upregulation of GluN2A-dependent
survival signals, including p-Akt, p-ERK, and postsynaptic
density protein-95, suggesting that it protects neurons against
postischaemic neurovascular injury involving activation of
GluN2A/Akt/ERK pathways [37]. Preadministration of geni-
poside at 5, 10, and 20 mg/kg protected Sprague-Dawley rats
against hepatic ischemia/reperfusion injury by decreasing
alanine transaminase (ALT), aspartate transaminase (AST),
lactate dehydrogenase, Bax, IL-6, monocyte chemotactic
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protein 1, and TNF-𝛼 levels, increasing Bcl-2, PI3K, p-Akt,
and mammalian target of rapamycin (mTOR) expressions,
and lowering inflammatory cell infiltration, cellular swelling,
and vacuolar degeneration [38].
Furthermore, treatment with geniposide at 15, 30, and
60 mg/kg through tail vein injection lowered the infarct
volume and suppressed the activation of microglial cells
in ischemic penumbra of ischemia/reperfusion-injured rats
induced by middle cerebral artery occlusion. In oxygen-
glucose deprivation- (OGD-) treated rat microglial cells,
geniposide at 12.5, 25, and 50𝜇g/mL restrained the increase of
cell viability and release of TNF-𝛼, IL-1𝛽, IL-6, IL-8, and IL-
10. Furthermore, it lowered OGD-induced increase of Toll-
like receptor 4 (TLR4) mRNA and protein levels. Geniposide
at 25 and 50 𝜇g/mL attenuated the phosphorylation of
ERK, I𝜅B, and p38 and suppressed nuclear transcriptional
activity triggered via NF-𝜅B p65 [39]. Additionally, it sig-
nificantly suppressed the upregulated mRNA and protein
expression of P2Y
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and inhibited the phosphorylation of
Raf-1, mitogen-activated protein kinase kinase 1/2 (MEK1/2),
and ERK1/2 both in OGD-induced rat brain microvascular
endothelial cells (BMECs) and in UDP-glucose stimulated
BMECs. Moreover, it notably reduced the production of IL-
8, IL-1𝛽, and monocyte chemotactic protein 1 in BMECs
treated with OGD [40]. In rat hippocampal slice culture,
it attenuated OGD-induced neuronal cell death. Besides,
geniposide exhibited a greater protective effect on the granule
cell layer than on the pyramidal cell layer including CA 1
and CA 3 region in the hippocampus [41]. In addition, it
increased the viability of neonate rat primary cortical neuron
with sodium dithionite-induced OGD/reperfusion [42].
In H9c2 cells, pretreatment with geniposide in gra-
dient concentrations of 2.5, 5, 10, 20, 40, 80, 160, and
320 𝜇M for 30 min elevated cell viability, lowered lactate
dehydrogenase levels, and suppressed cardiomyocyte apop-
tosis induced by hypoxia/reoxygenation. Furthermore, it
lessened oxidative stress products (ROS/reactive nitrogen
species andmalondialdehyde), elevated antioxidative enzyme
(total SOD) level, improved mitochondrial morphology, and
inhibitedmitochondrial calciumoverload and depolarization
of mitochondrial membrane, thus reversing mitochondrial
dysfunction. Moreover, geniposide upregulated Bcl-2 and p-
Aktserine473 levels, downregulated Bax level, caspase-3 mRNA
expression, and the protein expression of cleaved caspase-
3 and cytochrome-c, and these effects were partially coun-
teracted by exendin (9-39) or LY294002, suggesting that it
inhibits hypoxia/reoxygenation-induced myocardial apopto-
sis through reversing mitochondrial dysfunction, an effect
in part due to activation of GLP-1R and PI3K/Akt signaling
pathway [43].
2.5. Hepatoprotective Activity. Geniposide modified abnor-
mal metabolism induced by ethanol exposure by alleviat-
ing disorders relating to amino acid metabolism and the
oxidative stress state in alcohol-induced liver injury model
mice [44]. Intragastric administration of geniposide at 20, 40,
and 80 mg/kg notably inhibited the acute alcohol-induced
increase of both serum ALT/AST and hepatic lipid peroxida-
tion levels. Furthermore, it increased the hepatic GSH, GSH
transferase, GSH-Px, CuZn-SOD, and catalase (CAT) levels.
Moreover, geniposide increased hepatic mRNA expressions
of CuZn-SOD and CAT, indicating that it protects against
acute alcohol-induced liver injury by upregulating the expres-
sion of the main antioxidant enzymes and thus improved
alcohol-induced oxidative stress injury in the liver [45].
Treatment with geniposide at 25, 50, and 100 mg/kg for 6
weeks ameliorated liver histology by decreasing the elevated
liver index (liver weight/body weight); serum ALT and AST
in high-fat diet caused nonalcoholic steatohepatitis in model
rats. Geniposide reduced total cholesterol, triglycerides, and
free fatty acids in serum and liver. Additionally, it inhib-
ited cytochromes P450 2E1 expression and elevated PPAR𝛼
expression [46].
In Sprague-Dawley rats, intragastric administration of
geniposide at 25, 50, and 100 mg/kg blocked 𝛼-naphthyli-
sothiocyanate- (ANIT-) induced changes in serum markers
for liver injury. Moreover, geniposide decreased basolateral
bile acids uptake by repressing organic anion transporting
polypeptide 2. Furthermore, it markedly elevated canalicular
bile acids secretion via bile acids export pump, subsequently
stimulating bile flow during cholestasis. Meanwhile, genipo-
side significantly increased mRNA levels of organic solute
transporter 𝛽. In addition, farnesoid X receptor, pregnane X
receptor, and small heterodimer partner were activated, indi-
cating the attenuation of ANIT-induced hepatotoxicity and
cholestasis in rat via regulation of enzymes and transporters
responsible for bile acids homeostasis [47]. In ICR mice,
treatment with geniposide at 50 mg/kg for 5 days mitigated
ANIT-induced cholestasis and liver injury. Furthermore, it
normalized the altered gene transcription related to bile acid
metabolism and transport and suppressed the activation and
expression of STAT3 [48].
Pretreatment of mice with geniposide at 20, 40, and
80 mg/kg for 7 days by intragastrical administration at-
tenuated Tripterygium glycosides- (270 mg/kg) induced el-
evation of serum ALT/AST, hepatic malondialdehyde, and
proinflammatory cytokine TNF-𝛼 level. Moreover, it in-
creased Tripterygium glycosides-induced downregulation of
biomarkers, including hepatic GSH level; activities of GSH
transferase, GSH-Px, SOD and CAT, and anti-inflammatory
cytokine IL-10 were observed. In addition, it promoted the
mRNA expression of hepatic transforming growth factor-
beta1 (TGF-𝛽1) [49]. In human HepG2 hepatocytes, genipo-
side suppressed palmitate-induced ER stress and inhibited
hepatic lipid accumulation via secretion of apolipoprotein
B and associated triglycerides and cholesterol. Moreover,
lysosomal enzyme activities including V-ATPase were sig-
nificantly increased, and these effects were reversed by
bafilomycin, aV-ATPase inhibitor, suggesting that geniposide
enhances lysosomal activity, resulting in reduction of ER
stress and hepatic dyslipidemia [50]. Besides, it inhibited
palmitate-induced cell death via enhancement of lysosome
activity [51]. In AML12 cells, geniposide apparently blocked
TGF-𝛽1-induced mRNA and protein expression of type-I
collagen and phosphorylation of Smad2/3; ERK andAkt were
significantly repressed [52]. Taken together, geniposide might
be a potential therapeutic candidate for treatment of liver
diseases.
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2.6. Anti-Inflammatory Activity. Geniposide is reported to
relieve the secondary hind paw swelling and arthritis index
and reduce phosphorylated c-Jun N-terminal kinase (JNK)
expression and T helper 17 cell cytokines, while increas-
ing regulatory T-cell cytokines in mesenteric lymph node
lymphocytes (MLNL) and peripheral blood lymphocytes of
adjuvant arthritis rats [53]. Oral administration of geniposide
at 30, 60, and 120 mg/kg attenuated histopathologic changes,
decreased IL-2 level, and increased the level of IL-4 and
TGF-𝛽1 in MLNL. Moreover, it elevated the expression
of 𝛽2-adrenergic receptor and lowered the expression of
G protein-coupled receptor kinase 2, 𝛽-arrestin-1 and 𝛽-
arrestin-2, and level of cyclic adenosine monophosphate
of MLNL [54]. Furthermore, it facilitated the recovery of
arthritis and suppressed the colonic inflammation damage
through reducing the expression level of TNF-𝛼, IL-1, and
IL-6, elevating the production of IL-10 and blocking the
expression of phospho-p38 related proteins in fibroblast-
like synoviocyte (FLS) [55]. In collagen-induced arthritis rat,
oral administration of geniposide at 33, 66, and 132 mg/kg
attenuated histopathologic changes of MLN and decreased
the level of IL-6 and IL-17, while the levels of IL-4 and
TGF-𝛽1 in MLNL were increased. Additionally, geniposide
promoted the proliferation capability of MLNL and inhibited
the expressions of p-Raf, p-MEK, and p-ERK1/2 in MLNL
[56], and these results might highlight the anti-inflammatory
effect and possible mechanisms of geniposide in MLNL and
FSL of rheumatoid arthritis.
In LPS-induced mastitis model mice, intraperitoneal
administration of geniposide at 2.5, 5, and 10 mg/kg notably
attenuated the infiltration of inflammatory cells. Besides, it
decreased the expression of TNF-𝛼, IL-1𝛽, and IL-6 both
in LPS-induced mastitis model mice (2.5, 5, and 10 mg/kg)
and in LPS-stimulated primary mouse mammary epithelial
cells (25, 50, and 100 𝜇g/mL). In addition, it inhibited the
phosphorylation of I𝜅B-𝛼, NF-𝜅B, p38, ERK, and JNK and
the expression of TLR4, indicating that geniposide inhibits
inflammation through regulating TLR4 expression, resulting
in affection of the downstream NF-𝜅B andmitogen-activated
protein kinase (MAPK) signaling pathways [57]. In C57BL/6
mice after Helicobacter pylori infection, geniposide inhibited
vacuolating cytotoxin A gene expression, downregulated the
serum levels of IFN-𝛾, IL-1𝛽, and immunoglobulins A and
M and decreased the inflammatory maker cyclooxygenase
2 (COX-2) [58]. Furthermore, it notably inhibited proin-
flammatory cytokines through regulating NF-𝜅B and PPAR𝛾
pathways in dextran sulfate sodium-induced experimental
colitis in mice and LPS-triggered inflammation in Caco-2
cells. Besides, geniposide notably regulated the expressions
of zonula occludens-1 and occludin attenuated body weight
loss, disease activity index, colon length shortening, and
colonic pathological damage in dextran sulfate sodium-
induced colitis model mice [59].
In another study, administration of geniposide at 25 and
50 mg/kg notably elevated the decreased body weight and
improved experimental colitis and related symptoms in 2,4,6-
trinitrobenzene sulfonic acid-induced experimental ulcera-
tive colitis model rats. Geniposide inhibited inflammatory
cytokine release, including TNF-𝛼, IL-1𝛽, and IL-6, and
neutrophil infiltration (myeloperoxidase activity) in the
colon. At a concentration of 25-100 𝜇g/mL, geniposide
improved LPS-induced endothelial barrier dysfunction via
the dose-dependent upregulation of transepithelial electrical
resistance inCaco-2 cells. Furthermore, it lowered the protein
expression of NF-𝜅B, COX-2, inducible nitric oxide synthase
(iNOS), and myosin light-chain kinase (MLCK), increased
the expression of tight junction proteins (occludin and zonula
occludens-1), and accelerated AMPK phosphorylation both
in vivo and in vitro. Geniposide-reduced MLCK protein
expression was antagonized by both AMPK siRNA trans-
fection and AMPK overexpression, suggesting that geni-
poside improves barrier dysfunction via AMPK-mediated
inhibition of the MLCK pathway. Taken together, geniposide
improved 2,4,6-trinitrobenzene sulfonic acid-induced colitis
by attenuating inflammation and regulating the disrupted
epithelial barrier function via activating the AMPK signal-
ing pathway [60]. Moreover, it alleviated inflammation in
acute liver injury model mice and in LPS-stimulated THP-1
cells. Geniposide decreased the expressions of Methyl-CpG
binding protein 2, Sonic hedgehog, and GLIS family zinc
finger 1, while elevating Patched1 expression, suggesting that
it may be an effective modulator of Methyl-CpG binding
protein 2-hedgehog pathway during the pathogenesis of
inflammation [61]. Pretreatment with geniposide at 20, 40,
and 80 mg/kg reduced inflammatory cells and total protein
concentration in the bronchoalveolar lavage fluid of LPS-
induced acute lung injury model mice and furthermore
reduced levels of inflammatory mediators, including TNF-𝛼,
IL-6, IL-10 [62], and IL-1𝛽 were observed [63]. In addition,
it suppressed LPS-induced alveolar wall changes, alveolar
haemorrhage, and neutrophil infiltration in lung tissue by
reducing myeloperoxidase activity [62].
In primary mouse macrophages, geniposide significantly
suppressed the expression of TLR4 and the production of
TNF-𝛼, IL-6, and IL-1𝛽 induced by LPS and prevented LPS-
induced phosphorylation of I𝜅B-𝛼, p65, p38, ERK, and JNK.
Moreover, it inhibited the LPS-induced IL-8 production in
mTLR4 and mMD-2 cotransfected HEK293 cells [63]. In
murine microglial N9 cells, pretreatment with geniposide
at 40, 80, and 160 𝜇g/mL for 20 h suppressed the acti-
vation of cells and restrained the overproduction of NO,
intracellular ROS, and the expression of iNOS induced by
LPS (1 𝜇g/mL). Geniposide at 80 and 160 𝜇g/mL inhib-
ited LPS-induced drop-off of I𝜅B and phosphorylation of
p38 and ERK1/2 [64]. In murine macrophage RAW 264.7
cells, it decreased the expression of TNF-𝛼, IL-1, IL-6,
and IL-1𝛽 and furthermore suppressed activation of NF-
𝜅B and expression of TLR4 at both mRNA and protein
levels [65, 66]. Pretreatment with geniposide at 40, 80,
and 160 𝜇g/mL for 1 h dose-dependently exerted anti-
inflammatory effects through preventing the LPS-stimulated
NF-𝜅B, MAPK, and activator protein-1 signaling pathway
activation, subsequently blocking the overexpression of the
inducible enzymes iNOS and COX-2. Furthermore, genipo-
side inhibited the expression and release of inflammatory-
associated mediators TNF-𝛼, IL-6, prostaglandin E
2
, and NO
[67]. InHUVECs, treatmentwith geniposide at 25-100𝜇g/mL
for 24 h evidently decreased LPS-induced transcription
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and translation levels of IL-6 and IL-8 and blocked LPS-
induced HUVEC migration and U937 monocyte adhesion
to HUVECs. Moreover, geniposide inhibited the activation
of NF-𝜅B, degradation of I𝜅B-𝛼, and phosphorylation of
p38 MAPK and ERK1/2 in HUVECs stimulated by LPS,
indicating that it attenuates LPS-stimulated IL-6 and IL-8
production in HUVECs through inhibiting p38 MAPK and
ERK1/2 signaling pathways [68]. In summary, geniposide
has the potential to be a therapeutic agent in the treatment
of inflammatory diseases, including mastitis, colitis, and
arthritis.
2.7. Antidepressant-Like Activity. Treatment with geniposide
at 25, 50, and 100 mg/kg counteracted chronic unpredictable
mild stress-induced behavioral abnormalities by increasing
sucrose intake, improving crossing and rearing behavior in
open field test, and by shortening immobility and prolong-
ing swimming time in forced swimming test. Moreover,
geniposide ameliorated chronic unpredictable mild stress-
induced hyperactivity of hypothalamus-pituitary-adrenal
axis through reducing corticosterone serum level, adrenal
gland index, and hypothalamic corticotrophin-releasing hor-
mone mRNA expression. Additionally, it increased the
expression of hypothalamic glucocorticoid receptor 𝛼 at
both mRNA and protein levels in paraventricular nucleus,
suggesting that geniposide ameliorates the impaired gluco-
corticoid receptor 𝛼 negative feedback on corticotrophin-
releasing hormone expression and hypothalamus-pituitary-
adrenal axis and indicating that the therapeutic effects of
geniposide are essentially similar to fluoxetine [69]. In STZ-
induced diabetic mice, intragastric administration of geni-
poside at 50 and 100 mg/kg alleviated the elevated blood
sugar and immobility time in forced swimming test. Fur-
thermore, it upregulated brain-derived neurotrophic factor
levels and increased the mRNA expression of brain-derived
neurotrophic factor and tropomyosin-related kinase B in
hippocampus of diabetic mice, indicating that geniposide
alleviates depression-like behavior in STZ-induced diabetic
mice and suggesting that its mechanisms may partially
be associated with upregulating brain-derived neurotrophic
factor expression in brain [70].
2.8. Antioxidant Activity. In primary cultured hippocampal
neurons, pretreatment with geniposide increased the HO-1
expression and subsequently inhibited cell apoptosis stim-
ulated by 3-morpholinosydnonimine hydrochloride (SIN-
1, 1mM). Additionally, geniposide (10 𝜇M) enhanced the
nuclear translocation of nuclear factor-E2-related factor 2 and
activation of PI3K in the presence of SIN-1-induced oxidative
stress, and these effects could be retarded by LY294002
(10 𝜇M) and Zinc protoporphyrin (an inhibitor of HO-1,
10 𝜇M), indicating that it protects primary hippocampal
neurons from oxidative stress by regulating nuclear factor-
E2-related factor 2 translocation and downstreamantioxidant
protein HO-1 expression via PI3K/Akt signaling pathway
[71]. In another study, geniposide-induced luciferase activity
enhanced after transfecting PC12 cells with the AB1 enhancer
from the HO-1 gene, but not in the PC12 cells whose GLP-
1R genewas disrupted.Moreover, the neuroprotective activity
of geniposide in PC12 cells was blocked by the prevention
of HO-1 activity via Sn-protoporphyrin IX or short hairpin
RNA-mediated knockdown of GLP-1R, suggesting that GLP-
1R plays a critical role in geniposide-inducedHO-1 expression
to attenuate oxidative insults in PC12 cells [72].
2.9. Antiapoptotic Activity. Geniposide significantly reduced
the percentage of sodium nitroprusside-stimulated chondro-
cytes in G0/G1 phase and elevated percentage in S phase and
G2/M phase in vitro. In addition, it suppressed the apoptosis
of chondrocyte and the concentration of NO in the culture
supernatants. Moreover, it impacted sodium nitroprusside-
induced apoptosis of chondrocyte by reducing the concen-
tration of NO and promoting proliferation of chondrocytes,
and this effect was a probable and important mechanism
of geniposide preventing osteoarthritis [73]. Intraperitoneal
administration of geniposide at 2.5, 5, and 10 mg/kg inhibited
mammary gland apoptosis, Bax expression, and the phos-
phorylation of caspase-3 cleavage and p53 and augmented
Bcl-2 expression in LPS- (0.2 mg/mL) induced mastitis
model mice. In LPS- (1 𝜇g/mL) induced primary mouse
mammary epithelial cells, geniposide at 25, 50, and 100𝜇g/mL
downregulated the ratio of dead cells in a concentration-
dependent manner. Consistently, geniposide attenuated the
expressions of Bax and TLR4, caspase-3 cleavage, and the
phosphorylation of p53, while increasing Bcl-2 expression,
suggesting that the antiapoptotic property of geniposide is
due to its modulation of TLR4 and apoptosis-related factors
(p53, Bax, Bcl-2, and caspase-3) in LPS-induced mouse
mastitis [74]. Additionally, it significantly ameliorated cell
viability andmorphology, reduced the expression of Bax, P53,
and caspase-9, and upregulated the expression of Bcl-2 in
CoCl
2
-stimulated PC12 cells [75].
2.10. Immune-Regulatory Activity. Oral administration of
geniposide at 100 mg/kg for 12 weeks showed immune-
regulatory effects and inhibited the formation of atheroscle-
rotic lesions via lowering the dendritic cell numbers and
prevented dendritic cell maturation in bone marrow and
infiltration into lesions inApoE-knockoutmice [76]. Further-
more, it increased FoxP3 expression, elevated the number and
function of regulatory T cells, and improved the atheroscle-
rotic lesions progression partly via lipid regulation and
immunoregulation in ApoE-/- mice fed a high-cholesterol
diet [77].
2.11. Antisepsis Activity. In RAW264.7 cells, geniposide could
directly bind and neutralize LPS and it dose-dependently
blocked LPS-induced cytokines release, reduced the upreg-
ulated TNF-𝛼 and TLR4 mRNA expression, and inhibited
the phosphorylation of p38 MAPK. In vivo, treatment with
geniposide at 40mg/kg protected mice challenged with lethal
heat-killed Escherichia coli and downregulated the level of
serum endotoxin in endotoxemia mice [78]. Geniposide
exhibited high binding affinity for lipidA, the bioactive center
of lipopolysaccharide (LPS). In LPS-induced sepsis model
mice, geniposide lowered LPS levels and release of IL-6 and
TNF-𝛼 induced by LPS and exhibited protective activities on
liver, heart, and lung [79].
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2.12. Other Biological Activities
2.12.1. Cardioprotective Activity. Intragastric administration
of geniposide at 50 mg/kg for 7 weeks inhibited cardiac
hypertrophy induced by constriction of the transverse aorta
or by isoprenaline in mice. It also activated AMPK𝛼 and
decreased phosphorylated level of mTOR, ERK, and pro-
tein kinase double-stranded RNA-dependent-like ERK in
hypertrophic heart induced by constriction of the transverse
aorta. Furthermore, geniposide attenuated the expressions of
glucose regulated protein 78, X-box binding protein 1, and
activating transcription factor 6. GLP-1R blockade retarded
the antihypertrophic response and activation of AMPK𝛼
by geniposide. Besides, knockdown of GLP-1R impeded the
inhibitory effects of geniposide on cardiac hypertrophy in
vivo, suggesting that it protects against cardiac hypertrophy
via GLP-1R and AMPK𝛼 and indicating that it may be a
potential therapeutic candidate for cardiac hypertrophy [80].
2.12.2. Antinociceptive Activity. Geniposide concentration-
dependently exerted the protective effect against hydrogen
peroxide-caused oxidative damage in PC12 and HEK293 cells
expressing rat and human GLP-1R, but not in HEK293T cells
that do not express GLP-1R. Oral and subcutaneous admin-
istration of geniposide dose-dependently inhibited formalin-
induced tonic response, but not the acute flinching response.
Intrathecal administration of geniposide induced antinoci-
ception in a dose-dependent manner, and this effect was
completely reversed by spinal exendin (9-39), siRNA/GLP-
1R, and cyclic AMP/PKA pathway inhibitors, suggesting that
geniposide exerts antinociception during persistent pain by
activating the spinal GLP-1R [81].
2.12.3. Apoptotic Activity. In vitro, geniposide suppressed
adjuvant-induced arthritis (AIA) FLS proliferation in a dose-
dependent manner and induced typical apoptotic morpho-
logical characteristics including nuclear shrinkage and chro-
matin condensation and notably promoted the apoptosis rate
of AIA FLS. Furthermore, it reduced Bcl-2 mRNA level and
elevated Bax and caspase-3 mRNA levels and lowered protein
level of phosphorylated-ERK1/2, indicating that geniposide
induced AIA FLS apoptosis by regulating the apoptosis-
related gene expressions and preventing ERK signal pathway
[82].
2.12.4. Antithrombotic Activity. Geniposide at 20 mg/kg sup-
pressed thrombin/collagen-induced platelet aggregation with
52.8%/26.2% aggregation rate in rats ex vivo. At a concentra-
tion of 10-40 mg/kg, it inhibited venous thrombosis induced
by tight ligation of the inferior vena cava in mice, and the
𝐸𝐷
50
value was 18.4 mg/kg [83].
2.12.5. Antiviral Activity. Geniposide inhibited enterovirus
71 replication and viral internal ribosome entry site activity,
suggesting that it may be a potential chemopreventive agent
against enterovirus 71 infections [84].
2.12.6. Promelanogenesis Activity. In norepinephrine-treated
normal human epidermal melanocyte, geniposide enhanced
melanogenesis via stem cell factor/c-kit signalling in which
the expression of c-kit receptor was increased [85].
2.12.7. Antitumoral Activity. Geniposide at 50 and 100 𝜇M
was able to stabilize covalent attachments of the topoiso-
merase I subunits to DNA at sites of DNA strand breaks,
generating cleavage complexes intermediates so being active
as poisons of topoisomerase I, suggesting that DNA damage
induced by topoisomerase I poisoning may be one of the
possible mechanisms of antitumoral activity displayed by
geniposide [86].
3. Conclusion
Geniposide, the major iridoid glycoside of Gardeniae Fruc-
tus, has been isolated from nearly 40 species of plants
and most of which are used as traditional phytomedicines.
Increasing body of pharmacological evidence has emerged
for the multiple bioactive functions of geniposide, includ-
ing neuroprotective, antidiabetic, hepatoprotective, anti-
inflammatory, analgesic, antidepressant-like, cardioprotec-
tive, antioxidant, immune-regulatory, antithrombotic, and
antitumoral effects. The active mechanisms are related to
enhancement of SOD, GSH, CAT, IDE, PPAR𝛾, and FoxO1,
inhibition of ROS, NO, ALT, AST, and 𝛼-synuclein, and
regulation of signaling pathways such as AMPK, NF-𝜅B,
and PI3K/Akt. In vivo and in vitro studies showed that
geniposide could pass through the blood-brain barrier with
poor permeability [87, 88]. However, the poor blood-brain
barrier permeability of geniposide could be significantly
improved via structural modification [89] or prescription
with a messenger agent, such as borneol and muscone [88,
90]. Collectively, it has been suggested that geniposidemay be
a drug or lead compound for the prophylaxis and treatment
of several diseases, such as AD, PD, diabetes and diabetic
complications, ischemia and reperfusion injury, and hepatic
disorders.
However, the study of geniposide is only in the primary
stage since the molecular mechanisms and targets under-
lying pharmacological effects are not yet clearly defined.
At present, its clinical application is mainly in the form
of traditional Chinese preparations instead of geniposide
monomer. In addition, toxicity of geniposide has also been
reported, for example, hepatotoxicity [91, 92]; oral chronic
toxicity of geniposide in rats has also been reported which
resulted in the serum biochemistry, urinalysis, haematolog-
ical parameters, and relative organ weights being affected.
Furthermore, its usage has caused noticeable pathological
abnormalities in liver and kidney tissues [93]. Besides, it
shows two-way regulation on certain effects, which may
be related to the dosage and experimental subjects, but
the specific reasons are not very clear. Thus, further stud-
ies are required to verify and develop the safe use of
geniposide.
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